Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...

Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA ...

Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.